Editorial: Legalizing off-label marketing would compromise safety

04/15/2010 | St. Louis Post-Dispatch

The legalization of off-label marketing of drugs in the spirit of free speech, for which Botox maker Allergan argues in a lawsuit against the FDA, could ultimately threaten consumer safety, according to an editorial of the St. Louis Post-Dispatch. Allergan said banning such marketing is a violation of free-speech rights, and a hearing on the company's case is scheduled this month.

View Full Article in:

St. Louis Post-Dispatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA